Concord Biotech Limited — Investor Meet, 07-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Concord Biotech reported strong Q1 FY27 revenues of ₹257 Cr, up 26% YoY, with API segment growing 42% and exports surging 46%. Gross margins improved to 78.9%, and EBITDA reached ₹82 Cr (32% margin, up 190 bps YoY). Management is confident in sustaining momentum, targeting ₹3,000 Cr revenue in 5-6 years. Growth is broad-based across product categories. New ANDA approvals, Fusidic acid launch, and the nascent injectable facility (5% utilized) are key drivers. The company maintains a zero-debt status with ₹442 Cr cash, indicating a positive outlook for continued expansion.